| Literature DB >> 27450316 |
Xiaoying Xie1, Yunwen Bao1, Nengyong Ouyang2, Xinlu Dai1, Kunyi Pan1, Baiji Chen1, Yawen Deng1, Xiquan Wu1, Fengqin Xu1, Hongyu Li3, Songyin Huang4.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of both hospital and community infections globally. It's important to illuminate the differences between community-acquired MRSA (CA-MRSA) and hospital-acquired MRSA (HA-MRSA), but there have been confusions on the definition, especially for the MRSA isolates identified within 48 h of admission. This study aimed to determine the molecular characteristics and virulence genes profile of CA and HA-MRSA isolates identified less than 48 h after hospital admission in our region.Entities:
Keywords: Antimicrobial susceptibility; Methicillin-resistant Staphylococcus aureus; Molecular characteristics; Virulence gene
Mesh:
Substances:
Year: 2016 PMID: 27450316 PMCID: PMC4957337 DOI: 10.1186/s12879-016-1684-y
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Clinical features of the HA-MRSA and CA-MRSA strains
| Characteristic | CA-MRSA | HA-MRSA |
|
|---|---|---|---|
| ( | ( | ||
| n(%) | n(%) | ||
| Sex | |||
| Male | 11(47.8) | 24(61.5) | 0.427 |
| Female | 12(52.2) | 15(38.5) | |
| Age | |||
| ~ 18 | 5(21.7) | 3(7.7) | 0.149 |
| 19-60 | 11(47.8) | 16(41.0) | |
| > 60 | 7(30.4) | 20(51.3) | |
| Season | |||
| Mar. ~May | 9(39.1) | 1(2.6) | 0.001 |
| Jul. ~Aug. | 2(8.7) | 14(35.9) | |
| Sep. ~Nov. | 7(30.4) | 15(38.5) | |
| Dec. ~Feb. | 5(21.7) | 9(23.1) | |
| Clinical source | |||
| Skin lesion | 15(65.2) | 16(41.0) | 0.001 |
| Pus | 5(21.7) | 1(2.6) | |
| Sputa | 2(8.7) | 22(56.4) | |
| Bone | 1(4.3) | 0(0) | |
| Type of infection | |||
| Infection of skin and soft tissue | 20(87.0) | 11(28.2) | <0.001 |
| Pneumonia | 2(8.7) | 22(56.4) | |
| Infection of the surgical site | 0(0) | 6(15.4) | |
| Infection of bone and joint | 1(4.3) | 0(0) | |
| Underline disease | |||
| None | 11(47.8) | 13(33.3) | 0.147 |
| Diabetes | 5(21.7) | 5(12.8) | |
| Hypertension | 6(26.1) | 9(23.1) | |
| Tumor | 0(0) | 4(10.3) | |
| Brain injury | 1(4.3) | 10(25.6) | |
| Other | 2(8.6) | 6(15.4) | |
| Outcomes | |||
| Relapse | 5(21.7) | 9(23.1) | 0.809 |
| Improvement | 17(73.9) | 25(64.1) | |
| Death within 1 month | 1(49.4) | 3(7.7) | |
Fig. 1Antibiotic resistance rates of 62 MRSA isolates. CA-MRSA vs. HA-MRSA, *P < 0.05
Fig. 2SCCmec type and ST distribution of the 62 MRSA isolates. CA-MRSA vs. HA-MRSA, *P < 0.05. CA-MRSA, community-acquired methicillin-resistant Staphylococcus aureus; HA-MRSA, hospital-acquired methicillin-resistant Staphylococcus aureus; SCCmec, staphylococcal cassette chromosome mec; ST, sequence types
Detection of the 20 virulence genes of 62 MRSA isolates in this study
| Virulence genes | No. Of positive isolates | Virulence genes carriage of |
| |
|---|---|---|---|---|
| CA-MRSA | HA-MRSA | |||
| ( | ( | ( | ||
|
| 37(59.7) | 13(56.5) | 24(61.5) | 0.284 |
|
| 12(19.4) | 12(52.2) | - | |
|
| 12(19.4) | 7(30.4) | 5(12.8) | 0.039 |
|
| 12(19.4) | 3(13.0) | 9(23.1) | 0.097 |
|
| 2(3.2) | - | 2(5.1) | |
|
| 13(21.0) | 4(17.4) | 9(23.1) | 0.377 |
|
| 7(11.3) | 4(17.4) | 3(7.7) | 0.086 |
|
| 5(8.1) | 3(13.0) | 2(5.2) | 0.081 |
|
| 6(9.7) | 4(17.4) | 2(5.1) | 0.011 |
|
| 62(100.0) | 23(100.0) | 39(100.0) | |
|
| 56(90.3) | 20(87.0) | 36(92.3) | 0.357 |
|
| 61(98.4) | 23(100.0) | 38(97.4) | 0.545 |
|
| 3(4.8) | 2(8.7) | 1(2.6) | 0.134 |
| PVL | 28(45.2) | 11(47.8) | 17(43.6) | 0.670 |
Sea ~ seo, gene encoding staphylococcal enterotoxins; hla ~ hlg, gene encodingα-hemolysin ~ γ-hemolysin; tsst-1, gene encoding toxic shock syndrome toxin 1; PVL, gene encoding Panton-Valentine leukocidin
Detection of the virulence genes of MRSA in accordance with the clinical diagnosis of the associated infection
| Virulence gene | Number and percentage of the MRSA isolates, n(%) |
| ||
|---|---|---|---|---|
| Infection of the surgical site | Infection of skin and soft tissue | Pneumonia | ||
| ( | ( | ( | ||
|
| 4(66.7) | 18(58.1) | 15(62.5) | 0.422 |
|
| - | 11(35.5) | 1(4.2) | <0.001 |
|
| 1(16.7) | 6(19.4) | 4(16.7) | <0.001 |
|
| 4(66.7) | 4(12.3) | 3(8.9) | <0.001 |
|
| - | 1(3.2) | 1(4.2) | 1.000 |
|
| 3(50.0) | 6(19.4) | 3(8.9) | <0.001 |
|
| 2(33.3) | 4(12.3) | - | <0.001 |
|
| 2(33.3) | 2(6.6) | - | <0.001 |
|
| 2(33.3) | 3(9.7) | - | <0.001 |
|
| 6(100.0) | 31(100.0) | 23(95.8) | |
|
| 6(100.0) | 27(87.1) | 23(95.8) | <0.001 |
|
| 6(100.0) | 30(96.8) | 23(95.8) | 0.235 |
|
| - | 3(9.7) | - | |
| PVL | 3(50.0) | 12(38.7) | 12(50.0) | 0.210 |
Sea ~ see, seg ~ sej, sem ~ seo, gene encoding staphylococcal enterotoxins; eta and etb, gene encoding exfoliative toxin A and B; hla ~ hlg, gene encoding α-hemolysin ~ γ-hemolysin; tsst-1, gene encoding toxic shock syndrome toxin 1; PVL, gene encoding Panton-Valentine leukocidin
The infection of bone and joint group (n = 1) was not included in statistical analysis
The relationship of molecular characterization, antimicrobial resistance, and the main virulence factor profiles of 62 MRSA isolates
| PFGE profile | SCC | ST (n) | CA-MRSA (n) | HA-MRSA (n) | The main virulence factor profiles | Resistance profile |
|---|---|---|---|---|---|---|
| A(33) | I(2) | ST8(1) | 0 | 1 |
| CIP/CN/E/TET |
| ST239(1) | 0 | 1 | ||||
| III(30) | ST239(29) | 7 | 22 | |||
| ST1 (1) | 0 | 1 | ||||
| V(1) | ST5(1) | 0 | 1 | |||
| B(12) | III (11) | ST239(9) | 2 | 7 |
| CIP/CN/E/TET/RD |
| ST537(1) | 0 | 1 | ||||
| ST1(1) | 1 | 0 | ||||
| IVa(1) | 7(1) | 1 | 0 | |||
| C (8) | I(1) | ST59(1) | 1 | 0 |
| E/TET |
| III(1) | ST59(1) | 1 | 0 | |||
| IVa(3) | ST59(3) | 2 | 1 | |||
| IVd(3) | ST59(1) | 3 | 0 | |||
| ST239(1) | ||||||
| ST338(1) | ||||||
| D (2) | III(1) | ST950(1) | 1 | 0 |
| E |
| II(1) | ST239(1) | 0 | 1 | |||
| E (2) | III(2) | ST10(1) | 1 | 0 |
| E |
| ST3073(1) | 0 | 1 | ||||
| F (1) | I(1) | ST45(1) | 1 | 0 |
| E/TET |
| G (1) | III(1) | NT(1) | 0 | 1 |
| E/TET/RD |
| H (1) | IVa(1) | ST59(1) | 1 | 0 |
| E/TET |
PFGE pulsed-field gel electrophoresis, SCCmec staphylococcal cassette chromosome mec, ST sequence type, Sea ~ see, seg ~ sej, sem ~ seo, gene encoding staphylococcal enterotoxins; eta and etb, gene encoding exfoliative toxin A and B; hla ~ hlg, gene encodingα-hemolysin ~ γ-hemolysin; tsst-1, gene encoding toxic shock syndrome toxin 1; PVL Panton-Valentine leukocidin, CIP ciprofloxacin, CN gentamicin, E erythromycin, TET tetracycline, RD rifampicin, NT non-typable